OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Bevacizumab; Fosbretabulin
- Indications Glioma
- Focus Adverse reactions
- 07 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 20 May 2010 Trial design data will be presented in aposter at the 2010 ASCO Annual Meeting, according to an OXiGENE media release.
- 27 Jan 2010 New trial record